Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2113036 | Cancer Letters | 2013 | 7 Pages |
Abstract
In this study, we assessed if nafamostat mesilate may enhance anti-tumor effects of oxaliplatin on Panc-1 cells and pancreatic cancer mouse model. In combination treatment with nafamostat mesilate and oxaliplatin, NF-κB activation was inhibited by suppressing IκBα phosphorylation, and caspase-8-mediated apoptosis was more prominent than that treated with oxaliplatin alone, both in vitro and in vivo. Nafamostat mesilate reduced proliferation rate of Panc-1 cells as compared with oxaliplatin alone in vitro and enhanced oxaliplatin-induced tumor growth inhibition in vivo. Combination chemotherapy using nafamostat mesilate and oxaliplatin induces synergistic cytotoxicity in pancreatic cancer and could be a novel strategy for treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Takeshi Gocho, Tadashi Uwagawa, Kenei Furukawa, Koichiro Haruki, Yuki Fujiwara, Ryota Iwase, Takeyuki Misawa, Toya Ohashi, Katsuhiko Yanaga,